News

Lundbeckfonden Ventures News

Cambridge, UK and Indianapolis, US – 12 December 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 2 clinical trial of APD403 (intravenous and oral amisulpride) in chemotherapy induced nausea and vomiting (CINV) have been published (Herrstedt et al1) in the online edition of...
Company Release no. 20/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 06 December 2018   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company’s capital has been increased by 4,948,055 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 494,805.50 as a...
Capital increase without preferential subscription rights to the benefit of certain categories of investors Saint-Priest, France, December 6, 2018, 8:00 (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces the success of its private placement financing of €7.67 million through a capital increase by the issuance of new shares without preferential subscription...
Capital increase without preferential subscription rights to the benefit of certain categories of investors • Delivery of the new 8,700 sqm production facility expected in 2021 • Financial information update Saint-Priest, France, December 5, 2018, 6:00 p.m. (C.E.T.) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces the launch of a capital increase by...
Lund, Sweden, 18:00 CET 30 November 2018 – During November, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 30 November 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,755,917. BONESUPPORT AB Emil Billbäck, CEO +46 (0)...
November 27, 2018 09:00 AM Eastern Standard Time EDINBURGH, Scotland–(BUSINESS WIRE)–DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer....
Cambridge, UK and Indianapolis, US – 21 November 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial of BARHEMSYS(TM) (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting (PONV) have been published (Habib et al1) in the online edition...
Lund, Sweden, 08.00 CET, 19 November 2018 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, today announces positive top-line data from the CERTiFy (CERAMENT® Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). BONESUPPORT CEO Emil Billback said:” Successfully completing the ground-breaking CERTiFy study, to demonstrate...
OXFORD, England and SAN FRANCISCO – Nov. 15, 2018 – PsiOxus Therapeutics, Ltd. (PsiOxus) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced a research project to investigate the use of PsiOxus’ virus-based gene therapy for treating solid tumors that have been historically resistant to immunotherapy. This pre-clinical immuno-oncology research will utilize PsiOxus’...
1 2 3 52

Lundbeckfonden Ventures

News

ACACIA PHARMA ANNOUNCES POSITIVE CLINICAL RESULTS FOR APD403 IN CHEMOTHERAPY INDUCED NAUSEA & VOMITING PUBLISHED IN SUPPORTIVE CARE IN CANCER
12. December 2018
Veloxis Increases Share Capital in Connection with Exercise of Warrants
6. December 2018
Biom’up successfully closes a €7.67 million private placement financing
6. December 2018